These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

872 related articles for article (PubMed ID: 19663689)

  • 41. Lopinavir/ritonavir treatment in HIV antiretroviral-experienced patients: evaluation of risk factors for liver enzyme elevation.
    Meraviglia P; Schiavini M; Castagna A; Viganò P; Bini T; Landonio S; Danise A; Moioli MC; Angeli E; Bongiovanni M; Hasson H; Duca P; Cargnel A
    HIV Med; 2004 Sep; 5(5):334-43. PubMed ID: 15369508
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Mitochondrial DNA levels in fat and blood cells from patients with lipodystrophy or peripheral neuropathy and the effect of 90 days of high-dose coenzyme Q treatment: a randomized, double-blind, placebo-controlled pilot study.
    Rabing Christensen E; Stegger M; Jensen-Fangel S; Laursen AL; Ostergaard L
    Clin Infect Dis; 2004 Nov; 39(9):1371-9. PubMed ID: 15494915
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effect of lopinavir/ritonavir monotherapy on quality of life and self-reported symptoms among antiretroviral-naive patients: results of the MONARK trial.
    Spire B; Marcellin F; Cohen-Codar I; Flandre P; Boue F; Dellamonica P; Raffi F; Norton M; Van Philippe N; Delfraissy JF
    Antivir Ther; 2008; 13(4):591-9. PubMed ID: 18672538
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Improvements in cheek volume in lipoatrophic individuals switching away from thymidine nucleoside reverse transcriptase inhibitors.
    Benn P; Sauret-Jackson V; Cartledge J; Ruff C; Sabin CA; Moyle G; Linney A; Reilly G; Edwards SG
    HIV Med; 2009 Jul; 10(6):351-5. PubMed ID: 19490181
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Switching to darunavir/ritonavir monotherapy vs. triple-therapy on body fat redistribution and bone mass in HIV-infected adults: the Monarch randomized controlled trial.
    Guaraldi G; Zona S; Cossarizza A; Vernacotola L; Carli F; Lattanzi A; Nardini G; Orlando G; Garlassi E; Termini R; Garau M
    Int J STD AIDS; 2014 Mar; 25(3):207-12. PubMed ID: 24216034
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Depletion of mitochondrial DNA copies/cell in peripheral blood mononuclear cells in HIV-1-infected treatment-naïve patients.
    Maagaard A; Holberg-Petersen M; Kvittingen EA; Sandvik L; Bruun JN
    HIV Med; 2006 Jan; 7(1):53-8. PubMed ID: 16313293
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The role of nucleoside reverse transcriptase inhibitors in the fat redistribution syndrome.
    Nolan D; Mallal S
    J HIV Ther; 2004 May; 9(2):34-40. PubMed ID: 15238874
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and two nucleosides for maintenance therapy of HIV.
    Pulido F; Arribas JR; Delgado R; Cabrero E; González-García J; Pérez-Elias MJ; Arranz A; Portilla J; Pasquau J; Iribarren JA; Rubio R; Norton M;
    AIDS; 2008 Jan; 22(2):F1-9. PubMed ID: 18097218
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Decreased mitochondrial DNA content in subcutaneous fat from HIV-infected women taking antiretroviral therapy as measured at delivery.
    Nasi M; Pinti M; Chiesa E; Fiore S; Manzini S; Del Giovane C; D'Amico R; Palai N; Campatelli C; Sabbatini F; Roccio M; Tibaldi C; Masuelli G; Mussini C; Ferrazzi E; d'Arminio Monforte A; Cossarizza A;
    Antivir Ther; 2011; 16(3):365-72. PubMed ID: 21555819
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Nucleoside analogue-sparing strategy for the treatment of chronic HIV infection: potential interest and clinical experience.
    Joly V; Yeni P
    Antivir Ther; 2005; 10(1):29-40. PubMed ID: 15751761
    [TBL] [Abstract][Full Text] [Related]  

  • 51. No significant effect of uridine or pravastatin treatment for HIV lipoatrophy in men who have ceased thymidine analogue nucleoside reverse transcriptase inhibitor therapy: a randomized trial.
    Calmy A; Bloch M; Wand H; Delhumeau C; Finlayson R; Rafferty M; Norris R; Hirschel B; Cooper DA; Carr A;
    HIV Med; 2010 Sep; 11(8):493-501. PubMed ID: 20236365
    [TBL] [Abstract][Full Text] [Related]  

  • 52. First line zidovudine/lamivudine/lopinavir/ritonavir leads to greater bone loss compared to nevirapine/lopinavir/ritonavir.
    van Vonderen MG; Lips P; van Agtmael MA; Hassink EA; Brinkman K; Geerlings SE; Sutinen J; Ristola M; Danner SA; Reiss P
    AIDS; 2009 Jul; 23(11):1367-76. PubMed ID: 19424051
    [TBL] [Abstract][Full Text] [Related]  

  • 53. An introduction to nucleoside and nucleotide analogues.
    Squires KE
    Antivir Ther; 2001; 6 Suppl 3():1-14. PubMed ID: 11678469
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Resuppression of virus load after interruption in treatment with nevirapine and 2 nucleoside reverse-transcriptase inhibitors.
    Yozviak JL; Doerfler RE; Woodward WC
    Clin Infect Dis; 2002 Feb; 34(4):547-50. PubMed ID: 11797185
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Constant mitochondrial DNA levels in blood leukocytes of patients enrolled in a NRTI-free therapeutic trial (BIKS-2 study).
    Amellal B; Allavena C; André-Garnier E; Ferré V; Valantin MA; Delfraissy JF; Lafeuillade A; Bonmarchand M; Calvez V; Raffi F
    J Infect; 2007 Jun; 54(6):603-8. PubMed ID: 17207857
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Clinical manifestations and management of antiretroviral nucleoside analog-related mitochondrial toxicity.
    Moyle G
    Clin Ther; 2000 Aug; 22(8):911-36; discussion 898. PubMed ID: 10972629
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Depletion of mitochondrial DNA in HIV-1-infected patients and its amelioration by antiretroviral therapy.
    Miura T; Goto M; Hosoya N; Odawara T; Kitamura Y; Nakamura T; Iwamoto A
    J Med Virol; 2003 Aug; 70(4):497-505. PubMed ID: 12794710
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Therapeutic drug monitoring of lopinavir/ritonavir given alone or with a non-nucleoside reverse transcriptase inhibitor.
    Solas C; Poizot-Martin I; Drogoul MP; Ravaux I; Dhiver C; Lafeuillade A; Allegre T; Mokhtari M; Moreau J; Lepeu G; Petit N; Durand A; Lacarelle B
    Br J Clin Pharmacol; 2004 Apr; 57(4):436-40. PubMed ID: 15025741
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Impact of switching from lopinavir/ritonavir to atazanavir/ritonavir on body fat redistribution in virologically suppressed HIV-infected adults.
    Ferrer E; del Rio L; Martínez E; Curto J; Domingo P; Ribera E; Negredo E; Rosales J; Saumoy M; Ordóñez J; Gatell JM; Podzamczer D
    AIDS Res Hum Retroviruses; 2011 Oct; 27(10):1061-5. PubMed ID: 21166602
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Initial therapy with nucleoside reverse transcriptase inhibitor-containing regimens is more effective than with regimens that spare them with no difference in short-term fat distribution: Hippocampe-ANRS 121 Trial.
    Duvivier C; Ghosn J; Assoumou L; Soulié C; Peytavin G; Calvez V; Génin MA; Molina JM; Bouchaud O; Katlama C; Costagliola D;
    J Antimicrob Chemother; 2008 Oct; 62(4):797-808. PubMed ID: 18641035
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 44.